GlassScriptPhysician profile
Marc J Zuckerman
NPI 1245268168
$40,899.65
in general payments reported to CMS, 2019-2025
27 companies · $5,851 in 2025
The $5,851 reported for 2025 was more than what 91% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,806 · 2020: $151 · 2021: $749 · 2022: $617 · 2023: $1,551 · 2024: $26K · 2025: $5,851.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26K · Food and Beverage: $7,209 · Travel and Lodging: $869.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25,500.00 |
| Food and Beverage | $7,209.21 |
| Travel and Lodging | $869.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $27,512.40 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $4,859.10 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Intercept Pharmaceuticals, INC. | $1,864.40 | 2019-2023 | Ocaliva |
| Abbvie INC. | $1,271.11 | 2024-2025 | |
| Gilead Sciences, INC. | $1,183.00 | 2019-2025 | Epclusa, Livdelzi |
| Takeda Pharmaceuticals U.S.A., INC. | $686.84 | 2020-2025 | Entyvio, Gattex |
| Madrigal Pharmaceuticals | $684.00 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Biotech, INC. | $500.37 | 2023-2025 | Stelara, Tremfya, Simponi Aria |
| Ardelyx, INC. | $465.36 | 2023-2025 | Ibsrela |
| Pfizer INC. | $353.23 | 2019-2025 | |
| Genzyme Corporation | $189.01 | 2022-2024 | |
| Medtronic, INC. | $179.81 | 2021-2022 | |
| Enterra Medical, INC. | $153.60 | 2023 | |
| Cook Medical LLC | $147.80 | 2025 | Hemospray |
| Allergan, INC. | $147.20 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $140.51 | 2022-2025 | Dupixent |
| Regeneron Healthcare Solutions, INC. | $137.59 | 2023-2025 | Dupixent |
| Covidien LP | $113.15 | 2019 | |
| Exact Sciences Corporation | $101.32 | 2023 | Cologuard Collection Kit |
| Olympus America INC. | $95.04 | 2024-2025 | Evis Exera III Colonovideoscope, Gastrointestinal Videoscope, Olympus |
| Boston Scientific Corporation | $25.81 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $21.92 | 2025 | Iqirvo |
| Ambu INC. | $21.79 | 2021 | |
| Ferring Pharmaceuticals INC. | $17.61 | 2023 | Rebyota |
| Apollo Endosurgery US INC | $15.11 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.57 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Zuckerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.